BRISTOL MYERS SQUIBB CO — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that BRISTOL MYERS SQUIBB CO filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $48.19B | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $48.30B | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | $45.01B | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | $46.16B | Feb 12, 2025 |
| FY2023 | Dec 31, 2021 | $46.39B | Feb 13, 2024 |
| FY2020 | Dec 31, 2020 | $11.07B | Feb 10, 2021 |
| FY2020 | Sep 30, 2020 | $10.54B | Feb 10, 2021 |
| FY2020 | Jun 30, 2020 | $10.13B | Feb 10, 2021 |
| FY2020 | Mar 31, 2020 | $10.78B | Feb 10, 2021 |
| FY2020 | Dec 31, 2019 | $7.95B | Feb 10, 2021 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $5.45B | Feb 13, 2018 |
| FY2017 | Sep 30, 2017 | $5.25B | Feb 13, 2018 |
| FY2017 | Jun 30, 2017 | $5.14B | Feb 13, 2018 |
| FY2017 | Mar 31, 2017 | $4.93B | Feb 13, 2018 |
| FY2017 | Dec 31, 2016 | $5.24B | Feb 13, 2018 |
| FY2017 | Sep 30, 2016 | $4.92B | Feb 13, 2018 |
| FY2017 | Jun 30, 2016 | $4.87B | Feb 13, 2018 |
| FY2017 | Mar 31, 2016 | $4.39B | Feb 13, 2018 |
| FY2016 | Dec 31, 2015 | $4.29B | Feb 21, 2017 |
| FY2016 | Sep 30, 2015 | $4.07B | Feb 21, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $8.16B | Feb 10, 2021 |
| FY2020 | Sep 30, 2020 | $8.04B | Feb 10, 2021 |
| FY2020 | Jun 30, 2020 | $7.43B | Feb 10, 2021 |
| FY2020 | Mar 31, 2020 | $7.12B | Feb 10, 2021 |
| FY2020 | Dec 31, 2019 | $5.45B | Feb 10, 2021 |
| FY2020 | Sep 30, 2019 | $4.22B | Feb 10, 2021 |
| FY2020 | Jun 30, 2019 | $4.30B | Feb 10, 2021 |
| FY2020 | Mar 31, 2019 | $4.10B | Feb 10, 2021 |
| FY2019 | Dec 31, 2018 | $4.30B | Feb 24, 2020 |
| FY2019 | Sep 30, 2018 | $4.06B | Feb 24, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.05B | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | ($8.95B) | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | $8.03B | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | $6.33B | Feb 12, 2025 |
| FY2023 | Dec 31, 2021 | $6.99B | Feb 13, 2024 |
| FY2020 | Dec 31, 2020 | ($10.03B) | Feb 10, 2021 |
| FY2020 | Sep 30, 2020 | $1.87B | Feb 10, 2021 |
| FY2020 | Jun 30, 2020 | ($85.00M) | Feb 10, 2021 |
| FY2020 | Mar 31, 2020 | ($775.00M) | Feb 10, 2021 |
| FY2020 | Dec 31, 2019 | ($1.06B) | Feb 10, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.95B | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $11.16B | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | $9.30B | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | $9.51B | Feb 12, 2025 |
| FY2023 | Dec 31, 2021 | $10.20B | Feb 13, 2024 |
| FY2022 | Dec 31, 2020 | $10.05B | Feb 14, 2023 |
| FY2021 | Dec 31, 2019 | $6.15B | Feb 9, 2022 |
| FY2020 | Dec 31, 2018 | $6.33B | Feb 10, 2021 |
| FY2019 | Dec 31, 2017 | $6.47B | Feb 24, 2020 |
| FY2018 | Dec 31, 2016 | $5.01B | Feb 25, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.27B | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $8.41B | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | $7.77B | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | $7.81B | Feb 12, 2025 |
| FY2023 | Dec 31, 2021 | $7.69B | Feb 13, 2024 |
| FY2022 | Dec 31, 2020 | $7.66B | Feb 14, 2023 |
| FY2021 | Dec 31, 2019 | $4.87B | Feb 9, 2022 |
| FY2020 | Dec 31, 2018 | $4.55B | Feb 10, 2021 |
| FY2019 | Dec 31, 2017 | $4.75B | Feb 24, 2020 |
| FY2018 | Dec 31, 2016 | $4.98B | Feb 25, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.16B | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $15.19B | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | $13.86B | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | $13.07B | Feb 12, 2025 |
| FY2023 | Dec 31, 2021 | $16.21B | Feb 13, 2024 |
| FY2022 | Dec 31, 2020 | $14.05B | Feb 14, 2023 |
| FY2021 | Dec 31, 2019 | $8.21B | Feb 9, 2022 |
| FY2020 | Dec 31, 2018 | $7.07B | Feb 10, 2021 |
| FY2019 | Dec 31, 2017 | $5.28B | Feb 24, 2020 |
| FY2018 | Dec 31, 2016 | $3.06B | Feb 25, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.31B | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $1.25B | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | $1.21B | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | $1.12B | Feb 12, 2025 |
| FY2023 | Dec 31, 2021 | $973.00M | Feb 13, 2024 |
| FY2022 | Dec 31, 2020 | $753.00M | Feb 14, 2023 |
| FY2021 | Dec 31, 2019 | $836.00M | Feb 9, 2022 |
| FY2020 | Dec 31, 2018 | $951.00M | Feb 10, 2021 |
| FY2019 | Dec 31, 2017 | $1.06B | Feb 24, 2020 |
| FY2018 | Dec 31, 2016 | $1.22B | Feb 25, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $90.04B | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $92.60B | Feb 11, 2026 |
| FY2024 | Dec 31, 2023 | $95.16B | Feb 12, 2025 |
| FY2023 | Dec 31, 2022 | $96.82B | Feb 13, 2024 |
| FY2022 | Dec 31, 2021 | $109.31B | Feb 14, 2023 |
| FY2021 | Dec 31, 2020 | $118.48B | Feb 9, 2022 |
| FY2020 | Sep 30, 2020 | $125.54B | Feb 10, 2021 |
| FY2020 | Jun 30, 2020 | $128.08B | Feb 10, 2021 |
| FY2020 | Mar 31, 2020 | $129.29B | Feb 10, 2021 |
| FY2020 | Dec 31, 2019 | $129.94B | Feb 10, 2021 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $71.53B | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $76.22B | Feb 11, 2026 |
| FY2024 | Dec 31, 2023 | $65.67B | Feb 12, 2025 |
| FY2023 | Dec 31, 2022 | $65.70B | Feb 13, 2024 |
| FY2022 | Dec 31, 2021 | $73.31B | Feb 14, 2023 |
| FY2021 | Dec 31, 2020 | $80.60B | Feb 9, 2022 |
| FY2020 | Dec 31, 2019 | $78.25B | Feb 10, 2021 |
| FY2019 | Dec 31, 2018 | $20.86B | Feb 24, 2020 |
| FY2018 | Dec 31, 2017 | $21.70B | Feb 25, 2019 |
| FY2017 | Dec 31, 2016 | $17.36B | Feb 13, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $18.47B | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $16.34B | Feb 11, 2026 |
| FY2024 | Dec 31, 2023 | $29.43B | Feb 12, 2025 |
| FY2023 | Dec 31, 2022 | $31.06B | Feb 13, 2024 |
| FY2022 | Dec 31, 2021 | $35.95B | Feb 14, 2023 |
| FY2021 | Dec 31, 2020 | $37.82B | Feb 9, 2022 |
| FY2020 | Dec 31, 2019 | $51.60B | Feb 10, 2021 |
| FY2019 | Dec 31, 2018 | $14.03B | Feb 24, 2020 |
| FY2018 | Dec 31, 2017 | $11.74B | Feb 25, 2019 |
| FY2017 | Dec 31, 2016 | $16.18B | Feb 13, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $21.75B | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $21.72B | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | $21.17B | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | $21.15B | Feb 12, 2025 |
| FY2023 | Dec 31, 2021 | $20.50B | Feb 13, 2024 |
| FY2022 | Dec 31, 2020 | $20.55B | Feb 14, 2023 |
| FY2020 | Dec 31, 2019 | $22.49B | Feb 10, 2021 |
| FY2019 | Dec 31, 2018 | $6.54B | Feb 24, 2020 |
| FY2018 | Dec 31, 2017 | $6.86B | Feb 25, 2019 |
| FY2017 | Dec 31, 2016 | $6.88B | Feb 13, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.90B | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $14.91B | Feb 11, 2026 |
| FY2024 | Dec 31, 2023 | $28.77B | Feb 12, 2025 |
| FY2023 | Dec 31, 2022 | $25.50B | Feb 13, 2024 |
| FY2022 | Dec 31, 2021 | $23.82B | Feb 14, 2023 |
| FY2021 | Dec 31, 2020 | $21.28B | Feb 9, 2022 |
| FY2020 | Dec 31, 2019 | $34.47B | Feb 10, 2021 |
| FY2019 | Dec 31, 2018 | $34.07B | Feb 24, 2020 |
| FY2018 | Dec 31, 2017 | $31.16B | Feb 25, 2019 |
| FY2017 | Dec 31, 2016 | $33.51B | Feb 13, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.21B | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $10.35B | Feb 11, 2026 |
| FY2024 | Dec 31, 2023 | $11.46B | Feb 12, 2025 |
| FY2023 | Dec 31, 2022 | $9.12B | Feb 13, 2024 |
| FY2022 | Dec 31, 2021 | $13.98B | Feb 14, 2023 |
| FY2021 | Dec 31, 2020 | $14.55B | Feb 9, 2022 |
| FY2020 | Sep 30, 2020 | $19.44B | Feb 10, 2021 |
| FY2020 | Jun 30, 2020 | $19.93B | Feb 10, 2021 |
| FY2020 | Mar 31, 2020 | $15.82B | Feb 10, 2021 |
| FY2020 | Dec 31, 2019 | $12.35B | Feb 10, 2021 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $44.83B | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $49.43B | Feb 11, 2026 |
| FY2024 | Dec 31, 2023 | $39.53B | Feb 12, 2025 |
| FY2023 | Dec 31, 2022 | $38.95B | Feb 13, 2024 |
| FY2022 | Dec 31, 2021 | $44.37B | Feb 14, 2023 |
| FY2021 | Dec 31, 2020 | $50.34B | Feb 9, 2022 |
| FY2020 | Sep 30, 2020 | $44.61B | Feb 10, 2021 |
| FY2020 | Jun 30, 2020 | $46.11B | Feb 10, 2021 |
| FY2020 | Mar 31, 2020 | $46.11B | Feb 10, 2021 |
| FY2020 | Dec 31, 2019 | $46.15B | Feb 10, 2021 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3 | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | (4) | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | 3 | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | 2 | Feb 12, 2025 |
| FY2023 | Dec 31, 2021 | 3 | Feb 13, 2024 |
| FY2020 | Dec 31, 2020 | (4) | Feb 10, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 10, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 10, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 10, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 10, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3 | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | (4) | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | 3 | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | 2 | Feb 12, 2025 |
| FY2023 | Dec 31, 2021 | 3 | Feb 13, 2024 |
| FY2020 | Dec 31, 2020 | (4) | Feb 10, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 10, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 10, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 10, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 10, 2021 |